|
|||||
|
|
Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer |
|
| Authors: | J Baselga F Costa H Gomez C Hudis B Rapoport H Roche LS Schwartzberg O Petrenciuc M Shan WJ Gradishar |
| Affiliation: | 1.Massachusetts General Hospital Cancer Center,Boston,USA;2.Hosp Sirio Libanes,S?o Paulo,Brazil;3.Instituto Nacional de Enfermedades Neoplasicas,Lima,Peru;4.Memorial Sloan-Kettering Cancer Center,New York,USA;5.The Medical Oncology Centre of Rosebank,Johannesburg,South Africa;6.Institut Claudius Regaud,Toulouse,France;7.West Clinic,Memphis,USA;8.Bayer HealthCare Pharmaceuticals,Toronto,Canada;9.Feinberg School of Medicine,Northwestern University,Chicago,USA |
| Abstract: | |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |